NeuBase Therapeutics, Inc.
CIK 0001173281
Revenue (TTM)
—
Q3 Nov 2023
Net Income (TTM)
−$13.73M
−32.9% YoY
Q3 Nov 2023
EPS Diluted (TTM)
−$2.95
−11.8% YoY
Q3 Nov 2023
Gross Margin
—
Q3 Nov 2023
Operating Margin
—
Q3 Nov 2023
Net Margin
—
Q3 Nov 2023
Free Cash Flow (TTM)
−$22.93M
Q3 Nov 2023
Cash
$12.57M
Q3 Nov 2023
Total Debt
—
Q3 Nov 2023
Shares Outstanding
3.73M sh
Q3 Nov 2023
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.